About Raphas
Raphas is a company based in Seoul (South Korea) founded in 2006. The company has 100 employees as of December 31, 2024. Raphas operates in a competitive market with competitors including Enable Injections, Valeritas, CeQur, Micron Biomedical and EoFlow, among others.
- Headquarter Seoul, South Korea
- Employees 100 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Raphas Co. Ltd.
-
Annual Revenue
$18.46 M (USD)-2.58as on Dec 31, 2024
-
Net Profit
-$3.23 M (USD)45.8as on Dec 31, 2024
-
EBITDA
$125.68 K (USD)0as on Dec 31, 2024
-
Latest Funding Round
Not available
- Investors
-
Employee Count
100
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Raphas
Raphas is a publicly listed company on the KRX with ticker symbol 214260 in South Korea, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Raphas
Investors in Raphas
Raphas has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include KIC Europe.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
KIC Europe is focused on fostering innovation between Korea and the EU.
|
Locked | Locked | Locked |
Investor details for Raphas
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Raphas
Investment portfolio details for Raphas
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Raphas
Detailed financials for Raphas
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Raphas Comparisons
Peer comparison for Raphas
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Raphas
Raphas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enable Injections, Valeritas, CeQur, Micron Biomedical and EoFlow, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of a wearable drug delivery solution
|
|
| Locked | Locked | Locked |
Wearable insulin patch pumps are developed for transdermal delivery.
|
|
| Locked | Locked | Locked |
Wearable insulin delivery patches are developed for mealtime dosing.
|
|
| Locked | Locked | Locked |
Microneedle patches are developed for vaccine and drug delivery.
|
|
| Locked | Locked | Locked |
A wearable disposable insulin patch for diabetes patients is developed.
|
|
| Locked | Locked | Locked |
Provides wearable insulin delivery devices for diabetes patients.
|
Detailed competitors of Raphas
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Raphas
Complete news archive for Raphas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Raphas
Raphas was founded in 2006 and raised its 1st funding round 10 years after it was founded.
Raphas is headquartered in Seoul, South Korea.
As of Dec 31, 2024, the latest employee count at Raphas is 100.
Annual revenue of Raphas is $18.46M as on Dec 31, 2024.
Developer of microneedle technology for cosmetics and medical applications. This company manufactures microneedles for transdermal drug delivery and produces cosmetic and food products utilizing this technology. The company holds various certifications and approvals for its products in multiple regions. Its offerings include a cosmetic brand featuring microneedle technologies and a brand of health-focused food products.
Raphas's top competitors include Enable Injections, CeQur and Valeritas.
Yes, Raphas is publicly traded on KRX under the ticker symbol 214260.
Raphas has 1 investor. Key investors include KIC Europe.
The ticker symbol of Raphas is 214260 on KRX.